SynthesisFrontiers in neurology2020
Trimetazidine-Induced Parkinsonism: A Systematic Review.
Synthesis in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Trimetazidine in Chronic Coronary Syndrome and Coronary Artery Disease: A Narrative Review of Clinical Efficacy, Safety, and Current Guideline Position.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Cardiovascular Implications of the Enhanced Games: Performance Enhancing Drugs in Competition and Recreation.Sports medicine - open · 2026Review
- Review
- Trimetazidine-Profen Hybrid Molecules: Synthesis, Chemical Characterization, and Biological Evaluation of Their Racemates.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders.Current drug research reviews · 2025Review
- Neuroprotective and anticonvulsant effect of trimetazidine in a PTZ-kindling model of mice through modulation of the IL-1β/IL-1R1 and HMGB-1/TLR-4 axis.Frontiers in pharmacology · 2025Article
- Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study.Advances in therapy · 2022Article
- Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?Journal of diabetes science and technology · 2022Article
- Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1British journal of pharmacology · 2022Article
- Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study.International journal of environmental research and public health · 2020Article
- Trimetazidine in Heart Failure.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.